Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
322.90
-19.67 (-5.74%)
Streaming Delayed Price
Updated: 1:10 PM EST, Feb 2, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,794,016
Open
334.00
Bid (Size)
322.59 (4)
Ask (Size)
322.99 (2)
Prev. Close
342.57
Today's Range
317.00 - 335.30
52wk Range
231.87 - 384.44
Shares Outstanding
N/A
Dividend Yield
1.05%
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Why Eli Lilly Stock Is Under Pressure Today
Today 12:15 EST
The drugmaker's fourth-quarter earnings failed to impress investors.
Via
The Motley Fool
Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance
Today 10:36 EST
Via
Benzinga
Performance
YTD
-11.53%
-11.53%
1 Month
-11.53%
-11.53%
3 Month
-9.03%
-9.03%
6 Month
+2.89%
+2.89%
1 Year
+30.06%
+30.06%
More News
Read More
Looking for a Reliable Dividend Payer? Consider Buying This Blue-Chip Stock
Today 8:59 EST
Via
The Motley Fool
Eli Lilly Sinks On Mixed Earnings Report, But Boosts 2023 Earnings Outlook
Today 8:58 EST
Via
Investor's Business Daily
Eli Lilly Q4 Earnings Surpass Estimates
Today 8:21 EST
Via
Talk Markets
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Today 6:34 EST
Via
Benzinga
Preview: Eli Lilly's Earnings
February 01, 2023
Via
Benzinga
Is It Too Late to Buy Eli Lilly Stock?
January 26, 2023
Via
The Motley Fool
Darryle D. Schoepp, Ph.D., Former Merck and Eli Lilly Executive, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives
February 01, 2023
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
February 01, 2023
Via
The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
Via
Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
January 25, 2023
Via
Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
January 31, 2023
Via
InvestorPlace
Down 14.5%, Is Pfizer Stock a Screaming Buy?
January 30, 2023
Via
The Motley Fool
FDA Gives Conditional Approval For Eli Lilly's Drug For Rare Blood Cancer
January 30, 2023
Via
Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Via
MarketBeat
Exposures
Product Safety
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
January 27, 2023
Via
The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
Via
Benzinga
Good News, LLY Stock Invetors! Eli Lilly Is Poised for a Promising 2023.
January 27, 2023
Via
InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
January 26, 2023
Via
InvestorPlace
Could This New Drug Indication Be a Winner for Eli Lilly?
January 26, 2023
Via
The Motley Fool
2 Ultra-Safe Dividend Stocks to Own in 2023
January 25, 2023
Via
The Motley Fool
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
January 25, 2023
Via
The Motley Fool
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
January 24, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.